For the first time, patients choosing an oral GLP-1 for weight loss have two FDA-approved options: the Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026). Both are daily pills. Both activate the GLP-1 receptor. Both help people lose meaningful amounts of weight.

But they're not the same medication, and the differences between them are significant enough to make one a clearly better fit than the other for many patients. Here's the head-to-head comparison.

The Head-to-Head

Category Wegovy Pill Foundayo
Active ingredient Semaglutide (peptide) Orforglipron (small molecule)
Manufacturer Novo Nordisk Eli Lilly
Frequency Once daily Once daily
Food/water restrictions Must take on empty stomach with ≤4 oz water; no eating or drinking for 30+ minutes after None — take any time, with or without food and water
Average weight loss (highest dose, 72 weeks) ~14–15% ~12.4%
Maintenance dose 25 mg daily Up to 36 mg daily
Titration period ~16 weeks to reach 25 mg ~20 weeks to reach 36 mg
Starting price (savings programs) $149/month (intro doses) $149/month (intro doses)
Maintenance price (savings programs) Up to $299/month $299/month
Cardiovascular data Yes — semaglutide has SELECT trial data showing cardiovascular benefit Not yet — cardiovascular outcomes trial is ongoing
Available since Early 2026 April 2026

Convenience: Foundayo's Clearest Advantage

The single biggest practical difference between these medications is how you take them.

The Wegovy pill requires specific conditions for absorption. You must take it on an empty stomach — first thing in the morning is the most common approach — with no more than 4 ounces of plain water. Then you must wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. If you eat or drink too soon, the absorption of the medication can be significantly reduced.

Foundayo has none of these restrictions. Take it at breakfast with your coffee. Take it at lunch. Take it at bedtime with a glass of water. The small-molecule structure allows consistent absorption regardless of stomach contents.

This matters more than it might seem. The 30-minute fasting requirement of the Wegovy pill isn't hard to follow on any given day — but maintaining it perfectly every single day for months or years is where adherence breaks down. Morning routines are disrupted by travel, weekends, social situations, or simply forgetting. Each missed or improperly timed dose is slightly less effective medication. Over time, those small losses in consistency can meaningfully reduce results.

Real-world adherence matters: Clinical trial results assume perfect compliance — participants take every dose as directed under research conditions. In real-world practice, adherence is never perfect. A medication that's easier to take correctly is more likely to deliver results closer to what the trials showed. This is Foundayo's primary value proposition.

Weight Loss: Wegovy Pill's Edge

In clinical trials, the Wegovy pill produced approximately 14–15% body weight loss at the highest dose over 72 weeks, compared to Foundayo's approximately 12.4%. That's a meaningful difference — roughly 2–3 percentage points, which translates to several additional pounds for most patients.

However, several caveats apply. Clinical trial populations are selected and motivated. Real-world results for both medications will likely be somewhat lower than trial results. The gap between the two medications may narrow in real-world use if Foundayo's greater convenience leads to better adherence. And individual responses vary — some patients will respond better to one medication than the other, regardless of the average trial results.

For patients whose primary goal is maximum weight loss and who can reliably follow the fasting requirements, the Wegovy pill's higher average efficacy is a relevant advantage. For patients who prioritize simplicity and are likely to be more consistent with an unrestricted pill, Foundayo's convenience advantage may partly or fully offset its lower average efficacy.

Cardiovascular Data: A Meaningful Gap

Semaglutide — the active ingredient in both the Wegovy pill and Wegovy injection — has cardiovascular outcomes data from the SELECT trial, which showed a significant reduction in major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with overweight or obesity and established cardiovascular disease.

This is a major differentiator. For patients with existing heart disease, the Wegovy pill offers a benefit that goes beyond weight loss — it has demonstrated cardiovascular protection in a large, rigorous trial.

Foundayo does not yet have cardiovascular outcomes data. Eli Lilly has cardiovascular outcomes trials underway for orforglipron, but results are not expected for some time. This doesn't mean Foundayo lacks cardiovascular benefit — it may well have similar effects — but the data hasn't been generated yet.

For patients where cardiovascular risk reduction is a primary consideration, this data gap is clinically relevant and may favor semaglutide-based options.

Side Effects: Similar Profiles

Both medications share the common GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, and decreased appetite. These are generally most prominent during dose titration and tend to improve as the body adjusts.

Both carry a boxed warning for thyroid C-cell tumors and should not be used by patients with a personal or family history of medullary thyroid carcinoma or MEN2.

The side effect profiles are similar enough that choosing between the two medications based on tolerability alone is difficult. However, because they're chemically different compounds, a patient who doesn't tolerate one may tolerate the other — switching from Foundayo to the Wegovy pill (or vice versa) is a reasonable clinical strategy if side effects are problematic with the first choice.

Cost: Roughly Equivalent

Both medications are priced similarly through manufacturer savings programs. Starting doses for both come in at $149/month, with maintenance doses at approximately $299/month. The 12-month cost for self-pay patients is comparable for both — roughly $3,200–$3,600 depending on titration speed.

Insurance coverage is evolving for both medications. As FDA-approved products, both are potentially coverable by commercial plans and both are eligible for the Medicare GLP-1 Bridge program starting July 2026. Coverage decisions will likely favor one or the other on specific formularies — check with your insurer to see which is preferred on your plan.

The Molecule Matters

Beyond the practical differences, the molecular distinction between these medications is worth understanding because it has implications for the future of the category.

Semaglutide-based oral medications (the Wegovy pill, Rybelsus) are peptides — large, complex molecules that are inherently fragile in the digestive system. Making them work as pills required significant pharmaceutical engineering (the SNAC absorption enhancer) and strict dosing conditions.

Orforglipron (Foundayo) is a small molecule — simpler, more stable, and more easily absorbed without special conditions. Small molecules are also typically cheaper and easier to manufacture at scale than peptides, which could influence long-term pricing dynamics.

The success of Foundayo validates the small-molecule approach to oral GLP-1 development and opens the door for future compounds with similar properties. Several other small-molecule GLP-1 agonists are in development from multiple pharmaceutical companies.

Which One Is Right for You?

Consider Foundayo if: You want the simplest possible pill regimen with no timing or food restrictions. You've struggled with adherence to medications that require specific conditions. You're new to GLP-1 medications and want to start with the easiest option. You don't have established cardiovascular disease that makes the SELECT trial data relevant to your care.
Consider the Wegovy pill if: You can reliably follow the fasting/timing requirements. You want the higher average weight loss that semaglutide has demonstrated. You have established cardiovascular disease and value the cardiovascular outcomes data from the SELECT trial. You've responded well to semaglutide in other forms (Ozempic, Wegovy injection) and want to continue with the same compound in pill form.

For some patients, the choice will be obvious. For others, it's genuinely a judgment call — and discussing both options with your prescriber is the best way to arrive at the right decision for your specific situation.

The Bottom Line

Having two FDA-approved oral GLP-1 weight loss medications is unambiguously good for patients. More options mean better personalization, and the competition between Novo Nordisk and Eli Lilly is driving pricing that benefits consumers.

The Wegovy pill offers slightly higher average weight loss and proven cardiovascular benefits, at the cost of daily fasting requirements. Foundayo offers unmatched convenience at the cost of somewhat lower average efficacy and no cardiovascular outcomes data yet. Neither is universally better — both are effective, FDA-approved treatments for a condition that affects hundreds of millions of people.

Editorial Note: Oral GLP-1s provides independent information about oral GLP-1 medications. This article is for informational purposes only and does not constitute medical advice. Clinical trial results reflect averages; individual responses vary. Always consult a licensed healthcare provider to determine which medication is appropriate for your specific situation. Some links on this site may be affiliate links — see our About page for full disclosure.